Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

This study has been terminated.
(Insufficient power to show therapy difference at interim analysis.)
Information provided by (Responsible Party):
Samuel C. Dudley, Jr., Emory University Identifier:
First received: November 14, 2005
Last updated: August 21, 2014
Last verified: August 2014
The purpose of this study is to test whether the drug, atorvastatin, will be able to reduce the rate of return of the abnormal beats after using cardioversion. Atorvastatin is a drug approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol but is not approved for preventing abnormal heartbeats. In addition to lowering cholesterol, the drug reduces inflammation. Inflammation seems to help cause atrial fibrillation, a certain type of abnormal heartbeat. In animals, atorvastatin reduces the risk of this type of abnormal beats, and preliminary data in humans supports an effect of atorvastatin and other similar drugs that have the same action on reducing the risk of this type of abnormal beats. We, the researchers at Emory University, would like to learn if this drug could prevent the return of these abnormal heartbeats.

Condition Intervention Phase
Atrial Fibrillation
Drug: Atorvastatin
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

Resource links provided by NLM:

Further study details as provided by Emory University:

Primary Outcome Measures:
  • Time of Atrial Fibrillation Recurrence [ Time Frame: Upon recurrence, up to 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Comparison of Redox Potential for Cysteine Values [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]
  • Comparison of Redox Potential for Glutathione Values [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]
  • Comparison of Derivatives of Reactive Oxygen Metabolites Values [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]
  • Comparison of Isoprostanes Values [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]
  • Comparison of Interleukin-6 Values [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]
  • Comparison of Interleukin-1 Values [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]
  • Comparison of High Sensitivity C-reactive Protein [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]
  • Comparison of Tumor Necrosis Factor Alpha Values [ Time Frame: Baseline and 30 days ] [ Designated as safety issue: No ]

Enrollment: 64
Study Start Date: October 2005
Study Completion Date: October 2009
Primary Completion Date: November 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo taken daily
Drug: Placebo
Experimental: Atorvastatin
Atorvastatin at a dose of 80 mg daily
Drug: Atorvastatin
80 mg of Atorvastatin

  Show Detailed Description


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • > or = 18 years of age
  • Clinical diagnosis-abnormal heart beat known as atrial fibrillation/flutter (ECG documentation)
  • Able to swallow pill form of drug

Exclusion Criteria:

  • < 18 years of age
  • enrollment in another ongoing trial
  • paroxysmal atrial fibrillation
  • hemodynamic instability
  • atrial fibrillation ablation within 6 months of enrollment
  • a contraindication for anticoagulation
  • severe valvular heart disease
  • presence of single lead implantable cardioverter defibrillator
  • unstable angina
  • New York Heart Association (NYHA) Class IV heart failure
  • hyperthyroidism
  • uncontrolled hypertension (blood pressure > 180/100 at rest) on medications
  • an illness that would limit life expectancy to less than 1 year
  • use of statins within the previous 30 days
  • significant coronary artery disease or lipid abnormalities necessitating statin therapy
  • implanted devices for active management of arrhythmias by pacing or defibrillation
  • lack of access to a telephone
  • illicit drug use
  • alcohol abuse
  • hypersensitivity to atorvastatin by history
  • pregnancy
  • sexually active female subjects not on contraception or surgically sterilized
  • nursing mothers
  • chronic liver disease or abnormal liver function (elevated transaminases 1.5 times the upper limit of normal [ULN] of laboratory reference range)
  • severe renal disease (creatinine > 200 mmol/L)
  • inflammatory muscle disease or creatine kinase (CK) > 3 times ULN
  • concurrent treatment with cyclosporine, fibrates, or high-dose niacin
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00252967

United States, Georgia
Veteran Administration Medical Center/Emory University
Atlanta, Georgia, United States, 30033
Crawford Long Hospital
Atlanta, Georgia, United States, 30322
The Emory Clinic
Atlanta, Georgia, United States, 30322
Sponsors and Collaborators
Emory University
Principal Investigator: Samuel D. Dudley, Jr., MD, PhD Veterans Administration Medical Center
  More Information

Negi, S., Shukrullah, I., Veladar, E., Bloom, H., Jones, D., S.C. Dudley, Jr. (2010). Statin Therapy for Prevention of Atrial Fibrillation Trial (SToP AF trial). [Abstract]. ACC 2010. 10-A-11608-ACC.

Responsible Party: Samuel C. Dudley, Jr., MD, Emory University Identifier: NCT00252967     History of Changes
Other Study ID Numbers: IRB00024771  1137-2004 
Study First Received: November 14, 2005
Results First Received: April 21, 2014
Last Updated: August 21, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Emory University:
Reactive Oxgen Speers
Atrial Fibrillation
Oxidative Stress

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Cardiovascular Diseases
Heart Diseases
Pathologic Processes
Atorvastatin Calcium
Anticholesteremic Agents
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action processed this record on May 23, 2016